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Abstract: The levonorgestrel-containing intrauterine system is an extremely effective, reversible 
and safe form of long-term yet reversible birth control. In view of its efﬁ  cacy, it is a safer 
alternative to permanent contraceptive methods such as sterilization. It is especially useful in 
situations where use of estrogen-containing contraceptives is contraindicated. While menstrual 
disturbances are a common side effect, proper counseling improves compliance. In addition 
to its contraceptive effect, the levonorgestrel intrauterine system offers potential therapeutic 
beneﬁ  ts in other clinical contexts, including menorrhagia, symptomatic ﬁ  broids, endometriosis, 
and endometrial protection.
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Introduction
The levonorgestrel-containing intrauterine device is a very effective and safe form 
of reversible long-term birth control. In addition to its contraceptive effect, it offers 
potential non-contraceptive therapeutic beneﬁ  ts.
We reviewed the efﬁ  cacy, safety and clinical applications of the levonorgestrel-
containing intrauterine device (LNG-IUS, Mirena®). The search included the 
PubMed, Cochrane Controlled Trials Register and WHO publications on contra-
ception. We included randomized controlled trials, controlled clinical trials and 
systematic/clinical reviews published in the English language in peer-reviewed 
journals and guidelines published by the WHO and the National Institute for Clinical 
Excellence (NICE). The key words used to search data included IUD, IUD-IUS, 
contraception.
Rationale for IUD
Among the several long-acting contraceptive methods, the intrauterine device 
(IUD) is the most popular and overall it is second most popular contraceptive 
method worldwide after sterilization (Progress in Reproductive Health Research 
2002). The popularity of the IUD stems from the fact that in addition to providing 
long-lasting, highly effective, rapidly reversible contraception, it has no known 
effects on breast milk or breastfeeding; it does not interfere with sexual intercourse 
or with any type of medication; it is widely available throughout the world, it can 
used by women of any age or parity and following an abortion or miscarriage and 
ﬁ  nally once in place, its user can more or less forget about it with no further costs 
(WHO 2007). There is no evidence that use of IUD increases tubal infertility 
(Grimes 2000).Patient Preference and Adherence 2008:2 294
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In addition to its contraceptive effect, the LNG-IUS 
offers potential therapeutic beneﬁ  ts in other clinical contexts, 
including menorrhagia, symptomatic ﬁ  broids, endometriosis, 
and endometrial suppression.
Development and pharmacology 
of Mirena® intrauterine 
contraceptive device
The aim of progesterone-releasing intrauterine systems 
initially was to reduce IUCD expulsion, by the addition 
of ‘uterine relaxing hormones’ (Odlind 1996). This led 
to the development of Progestasert® (the ﬁ  rst hormonally 
impregnated device releasing 65 μg of progesterone per day) 
and Mirena® LNG-IUS (releasing 20 μg of levonorgestrel 
per day).
Mirena® LNG-IUS was developed by Leiras Oy, Turku, 
Finland, and was launched ﬁ  rst in Finland in 1990. It has a 
T-shaped body (32 × 32 mm) made of polyethylene with an 
elastomer sleeve consisting a 1 to 1 mixture of polydimeth-
ylsiloxane and 52 mg of levonorgestrel mounted around 
its vertical part. The sleeve is covered with a drug-release-
controlling membrane of medical grade polydimethylsilox-
ane that releases levonorgestrel over an extended time of up 
to 5 years at a practically constant rate. The initial release rate 
of levonorgestrel is 20 μg per 24 h, and at the end of 5 years 
the release rate is still above 10 μg per 24 h (Lähteenmäki 
et al 2000). The distal end of the T-frame contains 2 removal 
threads. The device also contains barium sulfate, which 
makes it visible on X-ray examination. Local delivery of 
LNG results in low but detectable serum levels of LNG 
(0.1–0.4 ng/mL), much lower than peak levels observed with 
other combined or progestin-only contraceptives containing 
levonorgestrel (ESHRE Workshop 2008).
Levonorgestrel is a highly effective progestin, with an 
estimated progestational potency 10 times greater than that 
of progesterone; it also exhibits some androgenic properties 
(Sitruk-Ware 2007). The recommended duration of use of 
the Mirena® coil is 5 years. Even though the licensed dura-
tion of action is 5 years, evidence suggests that it is effec-
tive as a contraceptive for up to 7 years (Sivin et al 1991). 
Furthermore, women who are aged 45 years or older when 
their LNG-IUS is inserted and are amenorrhoeic may keep 
it until they no longer need contraception, even if this is 
beyond the duration of UK Marketing Authorisation (NICE 
guidelines 2005).
Mirena® LNG-IUS is currently licensed in the UK as a 
5-year contraceptive agent (license awarded 1995), treatment 
for idiopathic menorrhagia (license awarded 2001), and 
to provide uterine protection during estrogen replacement 
therapy in perimenopausal and postmenopausal women 
(license awarded 2005). The second and third applications 
for Mirena® LNG-IUS are not licensed in the US or Canada 
(Varma et al 2006).
Mechanism of action
The LNG-IUS acts predominantly by preventing implan-
tation and sometimes by preventing fertilization. The 
contraceptive effects of the LNG-IUS are mediated via its 
progestogenic effect on the endometrium. Local intrauter-
ine delivery of levonorgestrel (LNG) results in extensive 
decidualization of endometrial stromal cells, atrophy of the 
glandular and surface epithelium, and changes in vascular 
morphology (suppression of spiral artery formation and pres-
ence of large dilated vessels) along with down-regulation of 
sex steroid receptors in all cellular components (Guttinger 
and Critchley 2007). The result is a thin decidualized endo-
metrium, an environment that is unsuitable for sperm sur-
vival, fertilization and implantation. The endometrial changes 
develop in the ﬁ  rst month after insertion and persist until 
the device is removed (Guttinger and Critchley 2007). By 
inactivating the endometrium and suppressing proliferation, 
it also decreases menstrual blood loss (MBL) and pain. The 
levonorgestrel released locally alters the quality of cervical 
mucus, making it hostile to the movement of sperm through 
the cervix (Jonsson et al 1991). Thus, the number and quality 
of sperm reaching the site of fertilization in the tube seems 
to be reduced in LNG-IUS users.
Ovulation is not suppressed as it has little inﬂ  uence on 
ovarian activity; women have normal estradiol values from 
the time of insertion through its 5-year life span (Luukkainen 
et al 1990) ensuring that the LNG-IUS would not expose the 
user to hypoestrogenism leading to osteoporosis (Bahamondes 
et al 2006). Although the anovulation rate is almost 85% at 
the beginning of use, this rate falls to less than 15% at the 
end of the ﬁ  rst year (Nilsson et al 1980). As ovulatory cycles 
occur in most, even amenorrheic, users, ovulation suppres-
sion is not the primary mode of action (Lähteenmäki et al 
2000). Serum levels of LNG are usually not sufﬁ  cient to sup-
press ovulation, as a release of 50 μg per 24 h of LNG would 
be necessary to completely inhibit ovulation (Lähteenmäki 
et al 2000). The local progestative effect of the LNG-IUS 
on the endometrium manifests within a period of 3 months 
and over after insertion (Zalel et al 2003). This means that it 
can take up to 3 months for the initial menstrual disturbances 
to settle. Women should be accordingly counseled so as to Patient Preference and Adherence 2008:2 295
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decrease the discontinuation rate of the LNG-IUS due to the 
initial menstrual disturbances.
Insertion
The LNG-IUS can be inserted at any time in the menstrual 
cycle if it is reasonably certain the woman is not pregnant. 
However compared with the Cu-IUD that is effective imme-
diately, it takes 7 days to provide effective contraceptive 
protection. Hence additional contraception or abstinence 
should be advised for 7 days after inserting the LNG-IUS 
unless inserted in the ﬁ  rst 7 days of the cycle or when 
switching from a different method of contraception unless 
the current contraceptive method is still effective (FSRH 
Guidance 2007). While the insertion procedure may be 
relatively easy compared with insertion of other IUDs, some 
women may need analgesia and cervical dilatation (Jensen 
et al 2008). IUDs can be inserted immediately after ﬁ  rst or 
second trimester abortion and from 4 weeks post partum, 
irrespective of the mode of delivery (El Tagy 2003; NICE 
2005). In complicated valvular heart disease, prophylactic 
antibiotics should be used at the time of insertion to prevent 
endocarditis (WHO 2004).
Contraindications
The LNG-IUS should be avoided in patients with unexplained 
vaginal bleeding. It is preferably avoided in the presence of 
sexually transmitted diseases such as chlamydia and gonor-
rhea. In a systematic review, Mohllajee et al (2006) reported 
that with IUD insertion in the presence of chlamydia infection 
or gonorrhea, subsequent pelvic inﬂ  ammatory disease (PID) 
rates were 0%–5%, compared with insertion in the absence 
of infection (0%–2%).
Therapeutic beneﬁ  ts of the
LNG-IUS
Contraceptive beneﬁ  ts
The LNG-IUS provides highly effective contraception and 
is equally efﬁ  cient in all age groups with the risk of failure 
similar throughout the life span of the device. The 5-year 
cumulative pregnancy rate per 100 users is 0.5 and the 
5-year Pearl rate 0.11 (Backman et al 2004). The cumulative 
pregnancy rate at 5 years is 0.5% (Thonneau and Almont 
2008). Its use in lactating women provides highly effec-
tive and acceptable contraception and does not negatively 
inﬂ  uence breast-feeding or the growth and development of 
breast-fed infants (Shaamash et al 2005). Women with an 
intrauterine pregnancy with an LNG-IUS in situ should be 
advised to have the LNG-IUS removed before 12 completed 
weeks’ gestation whether or not they intend to continue the 
pregnancy (NICE 2005).
It can be safely used in women with a past history of PID 
or ectopic pregnancy, women with ﬁ  broids, and in young 
nulliparous women (WHO 2004). The LNG-IUS is medi-
cally safe for women to use if oestrogen is contraindicated 
(NICE 2005).
The LNG-IUS is both safe and extremely efﬁ  cacious for 
use in nulliparous women with no greater risk of perforation 
or expulsion (Prager and Darney 2007). In fact the LNG may 
be protective against infection via thickening of the cervical 
mucus (Jonsson et al 1991) and decreased menstrual blood 
loss. Nulliparous users are at no increased risk for infection 
and infertility than multiparous users and it is safe to offer 
post-abortion placement of the LNG-IUS to nulliparous 
women (Prager and Darney 2007). In a randomized study of 
young nulliparous women (Suhonen et al 2004), the safety 
and acceptability of the LNG-IUS for contraception was 
observed to be as good as with oral contraceptives, with a 
high continuation rate. The discontinuation rate in the ﬁ  rst 
year of the LNG-IUS is 20%, indicating that acceptability 
is similar among nulliparous and parous women (Prager and 
Darney 2007).
In contrast to the copper IUDs, the LNG-IUS is not 
recommended for emergency contraception. The absence of 
embryotoxic copper ions and the relatively low serum levels 
of levonorgestrel obtained immediately following LNG-IUS 
insertion compared with standard hormonal emergency 
contraception suggests that it may not be effective (ESHRE 
Capri Workshop Group 2008).
The LNG-IUS has been favorably compared with other 
contraceptive methods. In randomized comparative trials 
(RCTs), pregnancy rates were significantly lower with 
the LNG-IUS than with copper devices (Sivin et al 1991; 
Andersson et al 1994; Pakarinen et al 2003), though a 
Cochrane review of 21 RCTs (French et al 2004) concluded 
that there is insufficient evidence to conclude that the 
LNG-IUS is more effective than copper IUDs. In a recent 
systematic review of the Cochrane Library for all IUD-related 
reviews (Grimes et al 2007), the LNG-IUS was found to 
have comparable efﬁ  cacy to that of IUDs with 250 mm2 
of copper, immediate post-partum, and post-abortal inser-
tion appeared safe and effective and prophylactic antibiot-
ics at the time of insertion appeared unwarranted except in 
populations with a high prevalence of sexually transmitted 
infections (STIs). The LNG-IUS and tubal sterilization have 
comparable high effectiveness, with the LNG-IUS a safer 
option, and all women, particularly young women, who are Patient Preference and Adherence 2008:2 296
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at high risk for sterilization regret, should be encouraged to 
consider the LNG-IUS in place of a surgical procedure that 
is potentially irreversible (Grimes and Mishell 2008).
Repeated use of the device has had favorable outcomes. 
The initial bleeding problems that are frequently observed 
after the insertion of the ﬁ  rst LNG-IUS do not recur after 
an immediate change from the ﬁ  rst IUS to the second IUS 
(Rönnerdag and Odlind 1999). In contrast to other long act-
ing progestin only contraceptives, LNG-IUS has no effect 
on bone mineral density (Inki et al 2007).
There does not seem to be a delay in the return of fertility 
following removal of the Mirena® coil with conception rates 
79.1/100 women at 12 months after removal (Andersson 
et al 1992).
Non-contraceptive beneﬁ  ts 
of the LNG-IUS
Menorrhagia
Available medical treatments for menorrhagia include the 
LNG-IUS, non-steroidal anti-inﬂ  ammatory drugs, antiﬁ  -
brinolytic drugs, progestogens, oral contraceptives, and 
danazol. The choice of medical treatment can depend on 
individual factors such as requirement for contraceptive 
and dysmenorrhea. However, ﬁ  rst-line therapy with drugs 
has variable efﬁ  cacy and, at best, oral medication reduces 
menstrual blood loss by only 50% (Istre and Qvigstad 2007). 
The immediate and intense suppression of the endometrium 
leads to over 90% reduction of menstrual blood loss over a 
period of 12 months (Anderson and Rybo 1990) along with 
signiﬁ  cant beneﬁ  cial increase in hemoglobin and ferritin 
levels (Xiao et al 2003).
In a randomized controlled trial (Hurskainen et al 2004) 
health-related quality-of-life outcomes associated with the 
LNG-IUS and hysterectomy was similar with ﬁ  nancial ben-
eﬁ  ts in favor of the LNG-IUS. In a Cochrane review of 10 ran-
domized control trials (Lethaby et al 2005), the LNG-IUS was 
more effective than other medical interventions, with a 90% 
reduction from baseline in menstrual blood loss. Although the 
LNG-IUS results in a smaller reduction in menstrual blood 
loss than endometrial ablation, there are no differences in the 
women’s rates of satisfaction or quality of life. In a Cochrane 
systematic review of 8 trials (Marjoribanks et al 2006), use of 
LNG-IUS was more cost effective, with levels of satisfaction 
and quality of life with an LNG-IUS system similar to those 
after surgical treatment such as transcervical endometrial 
resection or balloon ablation or hysterectomy. Further long-
term studies are needed to compare the effectiveness of the 
LNG-IUS against conservative surgical treatments.
Inherited bleeding disorders may be the cause of 
menorrhagia in up to 13% of women and the LNG-IUS is 
an effective treatment option in such women (Kadir and 
Chi 2007), as medical treatments may otherwise be contra-
indicated and surgery carries additional risks. It is also an 
effective treatment for menorrhagia in women receiving oral 
anticoagulation (Pisoni 2005).
The LNG-IUS is cost effective in the treatment of menor-
rhagia, while offering reliable contraception. Compared with 
oral contraceptives and surgical treatment, treatment strate-
gies employing the LNG-IUS are the most cost-effective 
in managing dysfunctional uterine bleeding in women 
not desiring additional children (Blumenthal et al 2006). 
LNG-IUS followed by endometrial ablation may be the most 
cost-effective treatment for menorrhagia, when compared 
with immediate surgery (Clegg et al 2007).
Endometriosis
The LNG-IUS delivers signiﬁ  cant amounts of levonorg-
estrel into the peritoneal ﬂ  uid (Lockhat et al 2005) and 
this may explain the pain relief in patients with peritoneal 
endometriosis.
Medical treatments that are based on the reduction of 
lesions or on ovarian estrogen suppression, cause profound 
hypoestrogenism inducing a decrease in bone mineral den-
sity and hence treatment is limited 6 months (d’Arcangues 
2006), although longer treatment with add-back hormone 
therapy is possible. In addition, there are systemic side 
effects, and the need for regular administration could affect 
compliance. In such patients the LNG-IUS can be a useful 
alternative.
In a systematic review on the use of LNG-IUS for symp-
tomatic endometriosis following surgery, post-operative use 
of the LNG-IUS reduced the recurrence of painful periods 
in women who have had surgery for endometriosis while 
there was insufﬁ  cient evidence for other beneﬁ  ts such as 
reduced likelihood of further surgery for endometriosis and 
improved long-term fertility (Abou-Setta et al 2006). In a 
randomized controlled trial, insertion of the Mirena® coil 
signiﬁ  cantly reduced the medium-term risk of recurrence of 
moderate or severe dysmenorrhea compared with expectant 
management following operative laparoscopy for symptom-
atic endometriosis (Vercellini et al 2003). In another RCT 
(Petta et al 2005), LNG-IUS and depot-GnRH-analog were 
equally effective in signiﬁ  cantly decreasing endometriosis-
related pain. However an advantage with LNG-IUS is the 
fact that it does not provoke hypoestrogenism while being 
effective for 5 years. There is insufﬁ  cient information on Patient Preference and Adherence 2008:2 297
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the efﬁ  cacy of the LNG-IUS in the possible prevention of 
endometriosis recurrence.
Adenomyosis
The LNG-IUS has been reported to be useful in women 
with adenomyosis, although studies have been limited by 
small numbers. Its use may signiﬁ  cantly reduce pain and 
abnormal bleeding associated with adenomyosis along with 
signiﬁ  cantly reduced adenomyotic lesions, as evaluated by 
the thickness of the junctional zone (Braghetoa et al 2007). 
A long-term study showed that the use of the LNG-IUS led 
to signiﬁ  cant pain relief, reduction in the uterine volume 
and menstrual blood loss volume, and improvements in 
hematologic indices in patients with adenomyosis (Cho 
et al 2008); however, there was a gradual increase in uterine 
volume, pain scores, and pictorial blood loss assessment 
chart scores at 2 years after insertion and the authors sug-
gested that to maintain the efﬁ  cacy of the LNG-IUS for 
the management of adenomyosis, a new device might be 
needed after 3 years.
Fibroids
The LNG-IUS appears safe and effective in the treatment 
of menorrhagia in women with uterine cavities distorted 
by submucosal ﬁ  broids (Soysal and Soysal 2005). A recent 
review (Kaunitz 2007) of the published literature sug-
gested that, in women with uterine ﬁ  broids, with or without 
menorrhagia, the LNG-IUS reduces menstrual blood loss 
and likely reduces menstrual pain while maintaining high 
contraceptive efﬁ  cacy. However, expulsion rates are higher 
and there is inconsistent evidence on whether the LNG-IUS 
decreases uterine/fibroid dimensions. Although symp-
tomatic improvement may not be uniform, these ﬁ  ndings 
indicate that the LNG-IUS is a useful therapeutic option for 
selected women with menstrual symptoms associated with 
uterine ﬁ  broids.
Endometrial protection
The targeted delivery of progestagen in the uterine cavity is 
a preferred route in women who need endometrial protec-
tion due to the absence of systemic side effects along with 
high efﬁ  cacy.
Use of oral tamoxifen as adjuvant therapy for women 
with breast cancer has improved survival rates. However, it 
exerts weak estrogenic effect on the endometrium and hence 
is associated with endometrial pathologies such as polyps, 
hyperplasia and endometrial cancer. In view of its proges-
tational effects, the LNG-IUS is an effective prophylaxis in 
the prevention of endometrial pathology in women receiving 
tamoxifen (Chan et al 2007; Gardner et al 2000).
The LNG-IUS adequately suppresses the endometrium 
during hormone replacement therapy with estrogens (Riphagen 
et al 2000) while avoiding the potential adverse systemic 
effects of progestogens. A literature review by Riphagen et al 
(2000) and a subsequent long-term study of post-menopausal 
women by Wildemeersch et al (2007a) highlighted the 
endometrial protection offered by the LNG-IUS in women 
receiving estrogen replacement therapy.
The LNG-IUS has been investigated in the treatment of 
non-atypical and atypical hyperplasia as a useful alternative 
to hysterectomy especially in younger women who still wish 
to become pregnant or in women who refuse operation or 
are in poor health. While studies (Wildemeersch et al 2007b; 
Varma et al 2008) suggest it may be an effective option for 
suppressing the endometrium, there have been reports of 
progression of atypical endometrial hyperplasia to adeno-
carcinoma despite intrauterine progesterone treatment with 
the levonorgestrel-releasing intrauterine system (Kresowick 
et al 2008). Hence extreme caution should be exercised and 
we need robust randomized controlled trials to evaluate 
the effectiveness of the LNG-IUS in treating endometrial 
hyperplasia.
Side effects
The adverse events of interest fall into 2 categories: those 
related to an intrauterine device, such as dysmenorrhea, 
irregular bleeding, ectopic pregnancy, and expulsion of the 
device; and those related to progestogens, such as bloating, 
weight gain, and breast tenderness. In a systematic review 
of the literature, reported cumulative discontinuation rates 
with the LNG-IUS were as high as 24% after 1 year and 33% 
after 2 years (NICE 2005).
Bleeding complications
Overall, the commonest reason for discontinuation is unac-
ceptable bleeding patterns.
Up to 60% of women stop using the LNG-IUS within 
5 years, which is similar to other IUDs, unacceptable vaginal 
bleeding and pain being the most common reasons for dis-
continuation (NICE 2005). Even though irregular bleeding 
and spotting are common during the ﬁ  rst 6 months following 
LNG-IUS insertion, oligomenorrhea or amenorrhea is likely 
by the end of the ﬁ  rst year of LNG-IUS use (NICE 2005). 
Since frequent irregular bleeding is common during the ﬁ  rst 
few months following system insertion, proper counseling 
of the patient about possible bleeding patterns is crucial in Patient Preference and Adherence 2008:2 298
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order to minimize premature LNG-IUS removals. Since 
amenorrhea is an expected outcome (occurring in about 20% 
of users at 12 months), adequate counseling provides reassur-
ance that the absence of bleeding does not generally signify 
pregnancy or other problems leading to high continuation rate 
and high level of patient satisfaction (Jensen et al 2008).
Information received at the insertion visit is strongly 
associated with increased user satisfaction among the users of 
the LNG-IUS (Backman et al 2002), the association between 
high user satisfaction and advance information being stron-
gest on the possibility of missing periods.
Uterine perforations
Incidence of uterine perforations related to the insertion 
of a LNG-IUS is around 2.6 per 1000 insertions (Van 
Houdenhoven et al 2006). Insertion in lactating women, 
even beyond 6 weeks after delivery, is an important risk 
factor. The manufacturer of the LNG-IUS currently recom-
mends that post-partum insertions should be postponed 
until 8 weeks after delivery. Uterine perforation at inser-
tion seems less likely to occur if a withdrawal rather than 
a push-out technique – the recommended technique for a 
LNG-IUS – is used.
Expulsion and displacement
Expulsion of an IUD occurs in approximately 1 in 20 women, 
and is most common in the ﬁ  rst 3 months after insertion 
(NICE 2005). Patients at increased risk of expulsion include 
nulliparous women, women with severe dysmenorrhea, and 
those with insertions immediately post partum or post abor-
tion. There is insufﬁ  cient evidence to indicate that expulsion 
rates are lower with LNG-IUS (Chrisman et al 2007). There 
are no differences in the rates of expulsion between Cu-IUDs 
and the LNG-IUS (FSRH 2007). As expulsion generally 
occurs within the ﬁ  rst few months, women should be encour-
aged to attend follow-up within 12 weeks of insertion.
It is rare for the LNG-IUS to get displaced and there is 
conﬂ  icting evidence on how best to manage these patients. 
Intra-peritoneal dislocated LNG-IUS results in plasma levo-
norgestrel levels 10 times higher (4.7 nmol/L) than those seen 
with LNG-IUS placed in utero. This high plasma levonorg-
estrel level suppresses ovulation and therefore it has been 
suggested that a misplaced LNG-IUS should be removed 
when pregnancy is desired, as opposed to the copper IUD 
that may be left intraperitoneally, especially if asymptomatic 
(Haimov-Kochman et al 2003). However pregnancies have 
also been documented with a displaced LNG-IUS (Budiman 
et al 2007).
Ectopic pregnancy
The LNG-IUS is a very effective contraceptive and the 
absolute risk of pregnancy (intrauterine and ectopic) is very 
low. A previous ectopic pregnancy is not a contraindication 
to the use of intrauterine contraception (FSRH 2007). The 
risk of ectopic pregnancy when using the LNG-IUS is lower 
than when using no contraception. The overall risk of ectopic 
pregnancy when using the LNG-IUS is very low, at about 1 in 
1000 in 5 years. If a woman becomes pregnant with the LNG-
IUS in situ, the risk of ectopic pregnancy is about 1 in 20 
(NICE 2005). Similar rates of ectopic pregnancy are reported 
for the LNG-IUS and Cu-IUDs (French et al 2004).
Infection
The risk of developing PID following LNG-IUS insertion is 
very low (less than 1 in 100) in women who are at low risk 
of STIs and removals due to PID among LNG-IUS users 
is below 1% at 1 year, and below 1.5% at 5 years (NICE 
2005). A systematic review reported that there is conﬂ  ict-
ing evidence on whether levonorgestrel IUD is associated 
with a lower risk of PID than other IUDs and any risk of 
upper-genital-tract infection after the ﬁ  rst month is small 
(Grimes 2000). The protective effect of the LNG-IUS may 
be due to impenetrable cervical mucus, endometrial changes, 
or reduced retrograde menstruation (Toivonen et al 1991). 
If a woman was to develop PID with the IUD in place, it 
may be reasonable to offer initial treatment without imme-
diate removal (WHO 2004). In rare cases of pelvic infec-
tion secondary to Actinomyces israelii, device removal in 
conjunction with antibiotic treatment is more successful at 
clearing the colonization than antibiotics alone (Bonacho 
et al 2001).
A woman who currently has an STI such as gonorrhea 
or chlamydia or is at very high risk should not have an IUD 
inserted as insertion may increase the risk of PID. If a high 
risk patient screens negative, then an IUD can be inserted 
and if the screen is positive, then an IUD can be inserted 
after treatment, if she is not at risk of reinfection by the time 
of insertion (WHO 2007). In exceptional circumstances, if 
other, more appropriate methods are not available or not 
acceptable, an IUD can be inserted in high risk individuals 
even if STI testing is not available. Presumptive treatment 
should be considered with a full curative dose of antibiot-
ics effective against both gonorrhea and chlamydia and 
inserting the IUD after completion of treatment. The patient 
should be carefully checked for signs of infection at follow-
up and treated accordingly while being advised to return 
at once if there are any signs of infection (WHO 2007). Patient Preference and Adherence 2008:2 299
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Farley et al (1992) reported that PID among IUD users is 
most strongly related to the background risk of STI and hence 
screening for chlamydia should always be considered prior 
to inserting the LNG-IUS.
A systematic review to assess the effectiveness of pro-
phylactic antibiotic administration before IUD insertion in 
reducing IUD-related complications and discontinuations 
within 3 months of insertion highlighted the low risk of 
IUD-associated infection, with or without use of antibiotic 
prophylaxis (Grimes and Schulz 2001). Another systematic 
review (Mohllajee et al 2006) suggested that women with 
chlamydial infection or gonorrhea at the time of IUD inser-
tion were at increased risk of PID relative to women without 
infection, the absolute risk of PID being low for both groups. 
However, whether IUDs increase the risk of PID in women 
with an STI at the time of insertion is not known (Mohllajee 
et al 2006).
Ovarian cysts
The use of the LNG-IUS is associated with a small risk of 
development of ovarian cysts (Inki et al 2002). The precise 
mechanism by which the ovarian cysts are caused is not 
known, but may be secondary to disturbances in the normal 
growth and rupture of follicles during LNG-IUS use. How-
ever in a prospective, randomized trial by Inki et al (2002) 
these were symptomless and showed a high rate (94%) of 
spontaneous resolution and hence no routine ultrasound 
screening is necessary of women using the LNG-IUS.
Other rare side effects
Unrecognized retention in the uterine cavity of the active 
part (hormone-releasing capsule) of an LNG-IUS may lead 
to secondary amenorrhea. Although LNG-IUS are inserted 
and removed without particular difﬁ  culty in most cases, it 
may be prudent to check the device following removal to 
ensure that the capsule remains attached to the rest of the 
device (Forrest et al 2008).
Hormonal complications
The systemic absorption of levonorgestrel may have the 
potential to cause hormonal side effects. The LNG-IUS 
releases 20 μg per day of levonorgestrel and so drug-
related adverse events are less frequent than with the oral 
preparations of progesterone, which result in higher serum 
concentrations.
However discontinuation due to hormonal (non-bleeding) 
problems is rare. While changes in mood and libido or weight 
gain are similar whether using the LNG-IUS or IUDs, there 
is an increased possibility of developing acne (NICE 2005). 
While some women may complain of headaches, women who 
have migraine with or without aura may use the LNG-IUS.
The use of the LNG-IUS has not been associated with 
an increased risk of breast cancer (Backman et al 2005). 
In women with a past history of breast cancer, Trinh et al 
(2007), reported that, overall, there was no increased risk of 
breast cancer recurrence associated with use of the LNG-IUS; 
subgroup analysis suggested that while the LNG-IUS is not 
associated with an increased risk of recurrence in patients 
who start using the LNG-IUS after completing their breast 
cancer treatment, women who developed breast cancer while 
using an LNG-IUS and who continued to use the LNG-IUS, 
showed a higher risk of recurrence of borderline statistical 
signiﬁ  cance. Hence additional research is needed to conﬁ  rm 
or refute these ﬁ  ndings (Trinh et al 2007).
Conclusion
Women contemplating undergoing sterilization or hysterec-
tomy seek a long-term solution for contraception or treatment 
of menorrhagia. The LNG-IUS is one of the most versatile 
forms of long-acting reversible method of contraception. 
New developments in the delivery of levonorgestrel-
releasing intrauterine devices such as the Femilisk® (parous 
women), the Femilisk Slim® (nulliparous women), and the 
frameless FibroPlant® levonorgestrel LNG-IUS possess 
features that may solve the main problems encountered with 
conventional IUDs (eg, expulsion, abnormal or excessive 
bleeding, and pain) (Wildemeersch 2007). The LNG-IUS 
system is an extremely effective contraceptive and has many 
non-contraceptive health beneﬁ  ts, including suppression of 
menstruation, maintenance of iron stores, improvement in 
dysmenorrheal, and endometrial protection for women on 
estrogen replacement therapy.
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